Free tool
Rare disease stocks
We cover 4 companies grouped under the Rare disease theme. The median market value in the group is $5.39B. Across the group, the median move over the past trading day is −0.98%. Price change over the past year runs from −16.3% to +219.5% across the middle 80 percent of the group, with a median of −1.6%.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
4 of 268 companies match these filters.Clear filters
| Ticker | Company | Market cap (USD) | Size | 1Y return | Next report |
|---|---|---|---|---|---|
| 0HNC.L | BioMarin Pharmaceutical Inc. | $9.93B | Mid cap | +12.36% | Oct 26, 2026 |
| 0HI3.L | Arrowhead Pharmaceuticals, Inc. | $6.98B | Mid cap | +308.24% | Nov 24, 2026 |
| CAMX.ST | Camurus AB (publ) | $3.80B | Mid cap | −15.56% | Nov 5, 2026 |
| 0RD1.L | Camurus AB (publ) | $2.84B | Mid cap | −16.59% | Nov 5, 2026 |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.